/ LEGN
Legend Biotech (LEGN) Shows Strong Q3 Performance Despite Revenue Shortfall
Legend Biotech posted Q3 2025 EPS of -$0.11 and revenue of $272.33 million, supported by strong demand for CARVYKTI®.
November 12, 2025Legend Biotech Reports Q1: EPS Beat, Miss on Revenue with $93.99 M
Legend Biotech Corporation has reported impressive financial outcomes for Q1, with CARVYKTI net trade sales reaching approximately $157 million.
May 13, 2024